Terminal · Institutions

Every 13F-reported equity position this quarter, with its quarter-over-quarter change — each row traces back to the SEC filing.

JOHNSON & JOHNSON 13F Holdings -- Portfolio & Top Positions (2026-06-30)

JOHNSON & JOHNSON (CIK 200406) reported $798.7M across 15 reported positions in its SEC 13F filing for 2026-06-30. Largest positions: PTGX ($300.2M, 37.59%), NBTX ($212.0M, 26.55%), MGTX ($89.7M, 11.23%), RAPP ($74.4M, 9.31%), CTNM ($32.4M, 4.06%). Source: SEC Form 13F.

RankTickerCompanyValue% PortfolioSharesAction
1PTGXPROTAGONIST THERAPEUTICS INC$300.2M37.59%2.4MHold
2NBTXNANOBIOTIX$212.0M26.55%5.6MHold
3MGTXMEIRAGTX HLDGS PLC$89.7M11.23%6.6MHold
4RAPPRAPPORT THERAPEUTICS INC$74.4M9.31%1.8MHold
5CTNMCONTINEUM THERAPEUTICS INC$32.4M4.06%2.0MHold
6LEGNLEGEND BIOTECH CORP$23.5M2.95%814,586Hold
7CVRXCVRX INC$20.7M2.59%4.0MHold
8XNCRXENCOR INC$12.0M1.51%748,062Hold
9CBRSCEREBRAS SYSTEMS INC$11.8M1.48%53,586New
10FATEFATE THERAPEUTICS INC$9.1M1.14%3.4MHold
11PRCTPROCEPT BIOROBOTICS CORP$8.1M1.01%357,939Hold
12NMRANEUMORA THERAPEUTICS INC.$3.1M0.39%1.8MHold
13VORVOR BIOPHARMA INC$989,2060.12%53,732Hold
14LABSTANDARD BIOTOOLS INC$256,6550.03%311,967Hold
15ACETADICET BIO INC$196,8110.02%22,779Hold
16RLYBRallybio Corporation$00.00%0Exited
17NNOXNano-X Imaging Ltd.$00.00%0Exited

Source: SEC Form 13F filings · as of 2026-06-30